Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Nutranomics, Inc. (NNRX) Releases Results From Clinical Studies Of Glucozyme™ For Patients With Type 2 Diabetes

|Includes: Nutranomics, Inc. (NNRX)

Nutranomics, a developer of nutritional food products, reports data from several human patient clinical studies regarding Glucozyme™, a proprietary nutritional supplement designed to assist in the reduction of blood glucose levels in patients with Type 2 diabetes.

NNRX conducted one study "in-house" while another was conducted in a Hispanic clinic in Salt Lake City, Utah, and one conducted by a clinic in Tokyo, Japan.

The three separate clinical studies measured both the fasting glucose levels and the HbA1-c levels of Type 2 diabetics for 30, 60, and 90 days, demonstrating Glucozyme's ability to reduce blood sugar levels and HbA1-c levels in patients by 22-28 percent within the 90-day period.

"The results of the three separate studies were overwhelmingly positive and show that Glucozyme is effective at reducing the blood sugar levels in patients across a diverse ethnic population," Dr. Tracy K. Gibbs, CEO of NNRX stated via news release. "Based on these results, we are now preparing to launch Glucozyme globally."

NNRX said that Glucozyme in upcoming weeks will be available for purchase on the company's website, and that it is educating its sales force and distributors on the product.

For more information, visit nutranomics.com

QualityStocks provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.qualitystocks.net